In this setting, novel biomarkers not yet routinely used in clinical practice, such as hemeoxygenase-1 (HO-1), and transforming growth factor beta (TGF-β), have been suggested as having great potential to help assessment of NAFLD [22,23,24,25,26]. This evidence concerns the gene TGFB1 and metabolic dysfunction-associated steatotic liver disease.